Gingivitis Clinical Trial
Official title:
The Clinical Investigation of Stannous Fluoride Toothpaste and a Newly Designed Toothbrush Compared to Colgate Cavity Protection Toothpaste and a Regular Toothbrush in Reducing Plaque and Gingivitis: A Three-Month Study in Thailand
Qualified subjects will be enrolled and randomly assigned to either of the two study groups based on their initial Plaque and Gingivitis scores. During the first visit, subjects will undergo three key procedures: 1) evaluation for baseline plaque and gingivitis, 2) brushing with the assigned regimen products for two minutes, and 3) assessment for post-brushing plaque only. Subjects will be provided with clear instructions for regimen product usage and will be expected to adhere to these instructions. Follow-up evaluations for plaque and gingivitis will be conducted at one week, six weeks, and three months after initiation of regimen product use. Throughout the study period, continuous monitoring for adverse events will be carried out for all subjects.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Subjects, ages 18-70, inclusive. - Availability for the three-month duration of the clinical research study. - Good general health. - Minimum of 20 uncrowned permanent natural teeth (excluding third molars). 5. Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index. - Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification). - Signed Informed Consent Form Exclusion Criteria: - Presence of orthodontic bands. - Presence of partial removable dentures. - Tumor(s) of the soft or hard tissues of the oral cavity. - Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). - Five or more carious lesions requiring immediate restorative treatment. - Antibiotic use any time during the one-month period prior to entry into the study. - Participation in any other clinical study or test panel within the one month prior to entry into the study. - Dental prophylaxis during the past two weeks prior to baseline examinations. - History of allergies to oral care/personal care consumer products or their ingredients. - On any prescription medicines that might interfere with the study outcome. - An existing medical condition that prohibits eating or drinking for periods up to 4 hours. - History of alcohol or drug abuse. - Pregnant or lactating subjects |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Colgate Palmolive |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Loe and Silness Gingival Index. | A Loe-Silness Gingival Index score from 0 to 3 will be assigned by the examining dentist to all scoreable surfaces of the maxillary and mandibular teeth using a dental light and dental mirror. A whole mouth mean score for each subject will be determined by adding the values given by the examining dentist to each scoreable surface and dividing that number by the total number of surfaces scored. | baseline, one week, six weeks and three months | |
Primary | Quigley and Hein Plaque Index | A Quigley-Hein Plaque Index score of 0 to 5 will be assigned to all scoreable disclosed surfaces of the maxillary and mandibular teeth using a dental light and dental mirror. A whole mouth score for each subject will be determined by adding the values given by the dental examiner to each scoreable surface and dividing that number by the total number of surfaces scored. | baseline, one week, six weeks and three months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05568290 -
Interleukin-38 Levels in Individuals With Periodontitis
|
||
Completed |
NCT04402996 -
Meteorin-like Levels in Individuals With Periodontitis
|
||
Not yet recruiting |
NCT06016023 -
Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
|
||
Not yet recruiting |
NCT05497895 -
The Assessment of Clinical Efficacy of Topical Application of 5% Thymoquinone Gel for Gingivitis Patients
|
Early Phase 1 | |
Completed |
NCT02884817 -
Essential Oil+ELA, Plaque and Gingivitis
|
Phase 4 | |
Completed |
NCT02552589 -
Effect of Toothpaste on the Reduction of Plaque and Inflammation
|
N/A | |
Completed |
NCT02633345 -
Effects on Tablets Containing Probiotic Candidate Strains
|
N/A | |
Completed |
NCT02980497 -
Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study
|
N/A | |
Unknown status |
NCT01956656 -
Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis
|
N/A | |
Completed |
NCT02515929 -
Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs
|
Phase 4 | |
Completed |
NCT02235532 -
Effects of Aloe Vera Toothpaste on Periodontal Parameters
|
N/A | |
Completed |
NCT02508987 -
Obesity and Oxidative Stress in Patients With Different Periodontal Status
|
N/A | |
Completed |
NCT01941797 -
Experimental Peri-implant Mucositis in Humans
|
N/A | |
Completed |
NCT01593540 -
Clinical Examination of Metal Free Interdental Brushes
|
Phase 4 | |
Unknown status |
NCT01197105 -
Evaluation Study of a Mouthwash Based on Schinus Terebinthifolius to Treat Gingivitis in Children
|
Phase 1/Phase 2 | |
Completed |
NCT01236963 -
Essential Oils Mouth Rinse and Dental Floss: Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation
|
N/A | |
Completed |
NCT02102295 -
Effects of Antioxidant Dentifrice on Gingivitis
|
Phase 3 | |
Completed |
NCT06140784 -
A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices
|
N/A | |
Completed |
NCT02937636 -
To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population
|
N/A | |
Completed |
NCT06212908 -
Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer
|
N/A |